NIH Precision Medicine Initiative: Implications for Diabetes Research.
In his January 2015 State of the Union address, President Barack Obama announced a new Precision Medicine Initiative (PMI) to personalize approaches toward improving health and treating disease (www.whitehouse.gov/precision-medicine). He stated that the goal of such an initiative was "to bring us closer to curing diseases like cancer and diabetes, and to give all of us access to the personalized information we need to keep ourselves and our families healthier." Since that time, the National Institutes of Health (NIH) has taken a leadership role in implementing the President's vision related to biomedical research (www.nih.gov/precisionmedicine). Here, we discuss the NIH component of the PMI, related ongoing diabetes research, and near-term research that could position the diabetes field to take full advantage of the opportunities that stem from the PMI.
Division of Diabetes, Endocrinology, and Metabolic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD fradkinj@mail.nih.gov.
Judith E
JE
Fradkin
Office of Scientific Program and Policy Analysis, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Mary C
MC
Hanlon
National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Griffin P
GP
Rodgers
D035843:Biomedical Research / Q000639:trends*; D003920:Diabetes Mellitus / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D009316:National Institutes of Health (U.S.) / Q000458:organization & administration / Q000639:trends; D009369:Neoplasms / Q000628:therapy; D057285:Precision Medicine / Q000639:trends*; D014481:United States